Gemtesa is an oral medication primarily used for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. The drug is owned by Urovant and contains the active ingredient vibegron. Gemtesa was first authorized for market use on December 23, 2020, and is available in tablet form. The drug holds a total of 2 patents, none of which have expired yet.
The generic version of Gemtesa is projected to be available after December 1, 2030, following the expiration of the drug's last patent. The last patent, US8247415, titled 'Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists,' is expected to expire on December 1, 2030. Furthermore, drug patent challenges against Gemtesa can be filed starting from December 23, 2024. Thus, the market can anticipate the launch of Gemtesa generic after the mentioned timeframe.
Gemtesa, with its active ingredient vibegron, effectively treats Overactive Bladder (OAB) characterized by symptoms such as urge urinary incontinence, urgency, and increased urinary frequency. vibegron, a beta-3 adrenergic agonist, works by relaxing the bladder muscle during the storage phase, thus increasing the bladder's storage capacity and reducing the symptoms of OAB.
Gemtesa holds two patents. The last patent of the drug, marked as US8247415, is titled 'Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists,' which is scheduled to expire on December 1, 2030. The availability of Gemtesa generic is largely dependent on the expiration of this patent. Below is the detailed information about the patent: